Sartorius Stedim Biotech SA Asset Resilience Ratio
Sartorius Stedim Biotech SA asset resilience ratio. Sartorius Stedim Biotech SA (DIM) has an Asset Resilience Ratio of 0.37% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Sartorius Stedim Biotech SA balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sartorius Stedim Biotech SA (2008–2025)
Asset resilience ratio of Sartorius Stedim Biotech SA from 2008 to 2025. This chart shows how Sartorius Stedim Biotech SA's Asset Resilience Ratio has changed over time. See DIM FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Sartorius Stedim Biotech SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sartorius Stedim Biotech SA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €28.90 Million | 0.37% |
| Total Liquid Assets | €28.90 Million | 0.37% |
Asset Resilience Insights
- Limited Liquidity: Sartorius Stedim Biotech SA maintains only 0.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sartorius Stedim Biotech SA Industry Peers by Asset Resilience Ratio
Compare Sartorius Stedim Biotech SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Eyebright Medical Technology Beijing Co Ltd
SHG:688050 |
Medical Instruments & Supplies | 1.51% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026 |
Medical Instruments & Supplies | 8.17% |
|
Airway
WAR:AWM |
Medical Instruments & Supplies | 80.18% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.29% |
Sartorius Stedim Biotech SA Asset Resilience Ratio by Year (2008–2025)
Sartorius Stedim Biotech SA asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Sartorius Stedim Biotech SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.10% | €8.10 Million ≈ $9.47 Million |
€8.02 Billion ≈ $9.37 Billion |
-0.02pp |
| 2024-12-31 | 0.12% | €9.90 Million ≈ $11.57 Million |
€8.26 Billion ≈ $9.65 Billion |
0.00pp |
| 2023-12-31 | 0.12% | €9.50 Million ≈ $11.11 Million |
€7.74 Billion ≈ $9.05 Billion |
-0.39pp |
| 2022-12-31 | 0.51% | €25.90 Million ≈ $30.28 Million |
€5.07 Billion ≈ $5.92 Billion |
+0.16pp |
| 2021-12-31 | 0.35% | €13.72 Million ≈ $16.04 Million |
€3.95 Billion ≈ $4.62 Billion |
+0.03pp |
| 2020-12-31 | 0.32% | €9.84 Million ≈ $11.51 Million |
€3.07 Billion ≈ $3.59 Billion |
-0.68pp |
| 2019-12-31 | 1.01% | €18.30 Million ≈ $21.39 Million |
€1.82 Billion ≈ $2.13 Billion |
-0.22pp |
| 2018-12-31 | 1.22% | €19.21 Million ≈ $22.46 Million |
€1.57 Billion ≈ $1.84 Billion |
+0.31pp |
| 2017-12-31 | 0.91% | €12.84 Million ≈ $15.01 Million |
€1.40 Billion ≈ $1.64 Billion |
+0.22pp |
| 2016-12-31 | 0.69% | €8.27 Million ≈ $9.66 Million |
€1.20 Billion ≈ $1.40 Billion |
-0.09pp |
| 2015-12-31 | 0.78% | €8.35 Million ≈ $9.76 Million |
€1.07 Billion ≈ $1.25 Billion |
+0.03pp |
| 2014-12-31 | 0.75% | €6.79 Million ≈ $7.94 Million |
€906.76 Million ≈ $1.06 Billion |
-0.02pp |
| 2013-12-31 | 0.77% | €6.70 Million ≈ $7.83 Million |
€871.23 Million ≈ $1.02 Billion |
+0.90pp |
| 2012-12-31 | -0.13% | €-1.05 Million ≈ $-1.23 Million |
€793.87 Million ≈ $928.11 Million |
+0.13pp |
| 2008-12-31 | -0.26% | €-1.69 Million ≈ $-1.98 Million |
€652.34 Million ≈ $762.66 Million |
-- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more